RWE Partnerships Gilead's collaboration with Certara to generate real world evidence for remdesivir shows a readiness to leverage data driven insights in clinical and market access decisions. This creates opportunities to offer integrated RWE platforms, outcomes research services, and pharmacovigilance solutions to inform regulatory strategies and payer negotiations.

Leadership Transition Leadership transition in commercial operations creates a window to engage the new decision maker on strategy and supplier evaluation. Tailor outreach with updated value propositions aligned to global sales and market access priorities.

Access and Equity Gilead's emphasis on health equity and improving access to care opens doors for partnerships with patient support programs, pricing analytics, and public sector collaborations. Propose solutions that help expand patient reach, affordability, and program effectiveness for diverse markets.

Manufacturing Partnerships The firm engages in licensing to produce generic versions, highlighting needs for robust manufacturing, supply chain visibility, and global distribution. Opportunity to offer contract manufacturing optimization, serialization, and distribution analytics to support scale and compliance.

Tech and Data The technology stack shows heavy use of data analytics and collaboration tools, signaling opportunities to introduce platform modernization, data integration, AI and ML capabilities, and cybersecurity solutions across R&D, manufacturing, and commercial teams.